Patents by Inventor Kenneth F. Blount

Kenneth F. Blount has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230201281
    Abstract: Compositions and methods for treating patients are disclosed. An example composition may include a vaginal microbiota composition. The vaginal microbiota composition may include a mixture of bacteria. The mixture of bacteria may include Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, and Lactobacillus rhamnosus.
    Type: Application
    Filed: June 1, 2021
    Publication date: June 29, 2023
    Applicant: FERRING B.V.
    Inventors: Dana M. WALSH, Heidi HAU, Kristi STRANDBERG, Kenneth F. BLOUNT, Lee A. JONES
  • Publication number: 20210283197
    Abstract: Microbiota restoration therapy compositions and methods for making and using microbiota restoration therapy compositions are disclosed. One example method is a method for enhancing the immune system of a patient. The method may include administering a microbiota restoration therapy composition to a patient with a primary condition. The method may also include administering a treatment for the primary condition to the patient. The treatment may be designed to treat the primary condition.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 16, 2021
    Applicant: FERRING B.V.
    Inventors: KENNETH F. BLOUNT, GREGORY J. FLUET
  • Publication number: 20200263223
    Abstract: Methods for assessing microbiota are disclosed. An example method for assessing microbiota may include obtaining a fecal sample from a patient, quantifying the relative abundance of bacteria from a selected group of taxonomic classes in the fecal sample, calculating a microbiome health index based on the relative abundance of bacteria from the selected group of taxonomic classes, and correlating the microbiome health index with a medical condition of the patient.
    Type: Application
    Filed: October 12, 2018
    Publication date: August 20, 2020
    Applicant: REBIOTIX, INC.
    Inventors: KENNETH F. BLOUNT, WILLIAM DOUGLAS SHANNON, ELENA DEYCH, COURTNEY JONES, GREGORY J. FLUET
  • Publication number: 20120295903
    Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
    Type: Application
    Filed: June 30, 2010
    Publication date: November 22, 2012
    Inventors: Kenneth F. Blount, Philip D.G. Coish, Brian R. Dixon, Jayhyuk Myung, David Osterman, Phil Wickens, Stephanie Avola, Nick Baboulas, Angelica Bello, Judd Berman, Harpreet Kaur, David Moon, Vinh Pham, Andrew Roughton, Jeffrey Wilson, Jeffrey A. Leiby, Dennis Underwood, Paul Adrian Aristoff, Heinrich J. Schostarez, Robert A. Chrusciel, Thomas R. Belliotti, Bruce R. Evans, Frank C. Sciavolino, Manuel A. Navia
  • Patent number: 8313901
    Abstract: Disclosed herein are methods and compositions related to the detection of conformational changes and interactions with trigger molecules in riboswitches.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 20, 2012
    Assignee: Yale University
    Inventors: Ronald R. Breaker, Kenneth F. Blount, Izabela J. Puskarz, John K. Wickiser
  • Publication number: 20120135417
    Abstract: Methods, compositions and assays that measure the effect of a test compound on induction of ligand-induced ribowitch-mediated transcription termination are disclosed. The methods and the assays are useful in identifying drug candidates that modulate transcription by binding to a riboswitch, for example.
    Type: Application
    Filed: June 2, 2010
    Publication date: May 31, 2012
    Inventors: Jayhyuk Myung, Kenneth F. Blount, Christen Douglas Forbes, David Osterman
  • Publication number: 20120077781
    Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
    Type: Application
    Filed: August 11, 2009
    Publication date: March 29, 2012
    Inventors: Robert Gadwood, Harpreet Kaur, Kevin Kells, Jeffrey A. Leiby, David Moon, Vinh Pham, Philip D.G. Coish, Kenneth F. Blount, Brian R. Dixon, Jayhyuk Myung, David Osterman, Stephanie Avola, Nick Baboulas, Angelica Bello, Judd Berman, Bruce R. Evans, Tan Quach, Heinrich J. Schostarez, Frank C. Sciavolino, Dennis Underwood, Phil Wickens, Jeffrey Wilson, Justin Wu
  • Publication number: 20100137440
    Abstract: The lysine riboswitch is a target for antibiotics and other small molecule therapies. Compounds can be used to stimulate, active, inhibit and/or inactivate the lysine riboswitch.
    Type: Application
    Filed: September 11, 2007
    Publication date: June 3, 2010
    Applicant: Yale University
    Inventors: Ronald R. Breaker, Jinsoo Lim, Kenneth F. Blount, Joy Wang, Narasimhan Sudarsan
  • Publication number: 20090305253
    Abstract: Disclosed herein are methods and compositions related to the detection of conformational changes and interactions with trigger molecules in riboswitches.
    Type: Application
    Filed: December 21, 2006
    Publication date: December 10, 2009
    Inventors: Ronald R. Breaker, Kenneth F. Blount, Izabela J. Puskarz, John K. Wickiser
  • Publication number: 20080269258
    Abstract: Riboswitches and modified versions of riboswitches can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.
    Type: Application
    Filed: November 8, 2005
    Publication date: October 30, 2008
    Inventors: Ronald R. Breaker, Jinsoo Lim, Kenneth F. Blount, Isabela Puskarz, Robert Batey